FDA Strengthens Warning About Risk of Neuropsychiatric Events With Montelukast
Diana Ernst, RPh The Food and Drug Administration (FDA) is requiring the addition of a Boxed Warning to the prescribing information for montelukast, following a review of study data and case reports…